Genvec (GNVC) 10-K 28 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 24, 2014	Jun. 28, 2013
Document Information [Line Items]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'GNVC	'	'
Entity Common Stock, Shares Outstanding	'	17,269,962	'
Entity Registrant Name	'GENVEC INC	'	'
Entity Central Index Key	'0000934473	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$4,769,045

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$5,249	$4,150
Investments (Note 3)	856	11,105
Accounts receivable, net	201	947
Prepaid expenses and other	337	226
Total current assets	6,643	16,428
Property and equipment, net (Note 4)	514	805
Restricted cash	97	0
Other assets	0	197
Total assets	7,254	17,430
Current liabilities:	'	'
Accounts payable	1,048	1,500
Accrued expenses and other (Note 5)	1,596	2,187
Total current liabilities	2,644	3,687
Total liabilities	2,644	3,687
Commitments and Contingencies (Note 7)	'	'
Stockholders' equity (Note 8):	'	'
Preferred stock, $0.001 par value; 5,000 shares authorized in 2013 and 2012; none issued and outstanding in 2013 and 2012	0	0
Common stock, $0.001 par value; 30,000 shares authorized in 2013 and 2012; 13,678 and 12,948 shares issued and outstanding in 2013 and 2012	14	13
Additional paid-in capital	280,398	279,518
Accumulated other comprehensive loss (Note 3)	-22	-27
Accumulated deficit	-275,780	-265,761
Total stockholders' equity	4,610	13,743
Total liabilities and stockholders' equity	$7,254	$17,430

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Per Share data, unless otherwise specified
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000	5,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	30,000	30,000
Common stock, shares issued	13,678	12,948
Common stock, shares outstanding	13,678	12,948

STATEMENTS_OF_OPERATIONS_AND_C

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Revenue from strategic alliances and research contracts (Note 6)	$3,682	$9,353
Operating expenses:	'	'
Research and development	5,492	14,348
General and administrative	8,484	9,102
Total operating expenses	13,976	23,450
Operating loss	-10,294	-14,097
Other income:	'	'
Interest and Other Income, net	275	42
Net loss	-10,019	-14,055
Basic and diluted net loss per share	($0.77)	($1.09)
Shares used in computation of basic and diluted net loss per share	12,948	12,940
Comprehensive Loss:	'	'
Net loss	-10,019	-14,055
Unrealized holding gain (loss) on securities available for sale	5	-19
Comprehensive loss	($10,014)	($14,074)

STATEMENTS_OF_STOCKHOLDERS_EQU

STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
In Thousands
Beginning Balance at Dec. 31, 2011	$26,538	$13	$278,239	($8)	($251,706)
Beginning Balance (in shares) at Dec. 31, 2011	'	12,958	'	'	'
Net loss	-14,055	0	0	0	-14,055
Unrealized change in investments, net	-19	0	0	-19	0
Restricted stock issued under stock incentive plans	0	0	0	0	0
Restricted stock issued under stock incentive plans (in shares)	'	-10	'	'	'
Stock Based Compensation	1,279	0	1,279	0	0
Ending Balance at Dec. 31, 2012	13,743	13	279,518	-27	-265,761
Ending Balance (in shares) at Dec. 31, 2012	'	12,948	'	'	'
Net loss	-10,019	0	0	0	-10,019
Unrealized change in investments, net	5	0	0	5	0
Restricted stock issued under stock incentive plans	1	1	0	0	0
Restricted stock issued under stock incentive plans (in shares)	'	730	'	'	'
Stock Based Compensation	880	0	880	0	0
Ending Balance at Dec. 31, 2013	$4,610	$14	$280,398	($22)	($275,780)
Ending Balance (in shares) at Dec. 31, 2013	'	13,678	'	'	'

STATEMENTS_OF_CASH_FLOWS

STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:	'	'
Net loss	($10,019)	($14,055)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	174	242
Non-cash charges for stock-based compensation	880	1,279
Impairment of long lived assets	229	0
Gain on sale of long lived assets	-286	0
Changes in current assets and liabilities, net	-407	1,806
Changes in non-current assets, net	100	-89
Net cash used in operating activities	-9,329	-10,817
Cash flows provided by investing activities:	'	'
Purchases of equipment	-376	-355
Proceeds from sale of property and equipment	550	0
Purchases of investment securities	-2,295	-28,632
Proceeds from sale and maturity of investment securities	12,549	39,840
Net cash provided by investing activities	10,428	10,853
Cash flows from financing activities:	0	0
Increase in cash and cash equivalents	1,099	36
Beginning balance of cash and cash equivalents	4,150	4,114
Ending balance of cash and cash equivalents	$5,249	$4,150

ORGANIZATION_AND_BUSINESS_DESC

ORGANIZATION AND BUSINESS DESCRIPTION	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
ORGANIZATION AND BUSINESS DESCRIPTION	'
	(1) ORGANIZATION AND BUSINESS DESCRIPTION
	GenVec, Inc. (GenVec, we, our, or the Company) is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis AG, Merial Limited, and the U.S. Government to support a portfolio of programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), and malaria. In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).
	Our core technology has the important advantage of localizing protein delivery in the body. This is accomplished by using our adenovector platform to locally deliver genes to cells, which then direct production of the desired protein. This approach reduces side effects typically associated with systemic delivery of proteins. For vaccines, the goal is to induce an immune response against a target protein or antigen. This is accomplished by using an adenovector to deliver a gene which causes production of an antigen, which then stimulates the desired immune reaction by the body.
	Our research and development activities yield product candidates that utilize our technology platform and represent potential commercial opportunities. For example, preclinical research in hearing loss and balance disorders through the delivery of the atonal gene using GenVec’s adenovector technology may have the potential to restore hearing and balance function. We are working with Novartis Institutes for BioMedical Research, Inc. (together with Novartis AG and its subsidiary corporations, including Novartis Pharma AG, Novartis), on the discovery and development of novel treatments for their hearing loss and balance disorders. There are currently no effective therapeutic treatments available for patients who have lost all balance function, and hearing loss remains a major unmet medical problem.
	We have multiple vaccines in development leveraging our core adenovector technology including our preclinical programs to develop vaccine candidates for the prevention of RSV and HSV. We also a program to develop a vaccine for malaria. In the field of animal health, we are working with Merial Limited to commercialize vaccines for the prevention of a major animal health problem, FMD. Development efforts for this program are also supported by the U.S. Department of Homeland Security (DHS) and in collaboration with the U.S. Department of Agriculture (USDA).
	On September 3, 2013, our former President and Chief Executive Officer, Cynthia Collins, departed the Company and resigned from the Company’s Board of Directors. Douglas J. Swirsky was appointed as the President and Chief Executive Officer of the Company and also was appointed to our Board of Directors.
	Our current operating strategy was adopted in September 2013, when we announced that our Board of Directors withdrew a Plan of Complete Liquidation and Dissolution of the Company (the Plan of Dissolution) that had been adopted by the Board of Directors on May 24, 2013, subject to stockholder approval. After announcing the approval of the Plan of Dissolution by the Board of Directors, we received several proposals for transactions with us, including transactions to purchase all or portions of our assets or to engage in mergers with private companies that were looking to use us principally as a means to become publicly traded. As part of the Board of Directors' efforts to seek to maximize the value for our stockholders and to provide stockholders with appropriate information for their consideration, the Board of Directors considered these proposals. The process that we went through in evaluating alternative proposals, the business developments during that time, the challenges in monetizing our assets in the near term for values the Board of Directors thought would be fair, and the time that the process took, led the Board of Directors to conclude that it was in the best interests of our stockholders to withdraw the Plan of Dissolution and pursue our current operating strategy. This operating strategy is focused on advancing the Company’s technology through partnerships. Consistent with this strategy, GenVec is no longer investing its own resources in the development of its RSV and HSV vaccine candidates as it pursues collaborators for these programs.
	In going through the process of considering the Plan of Dissolution and alternative transactions, we worked to terminate or further curtail a number of our contractual obligations and a significant portion of our operations. We also ceased to support some programs at the levels at which they were previously supported, or at all. On July 29, 2013, for example, we entered into a modification with the U.S. Naval Medical Logistics Command to terminate contractual obligations under our agreement related to malaria vaccine development efforts with the NMRC.
	Our business strategy is focused on entering into collaborative arrangements with third parties to complete the development and commercialization of our product candidates. In the event that third parties take over the development for one or more of our product candidates, the estimated completion date would largely be under the control of that third party rather than us. We cannot forecast with any degree of certainty which proprietary products or indications, if any, will be subject to future collaborative arrangements, in whole or in part, and how such arrangements would affect our development plan or capital requirements. Our programs may also benefit from subsidies, grants or government or agency-sponsored studies that could reduce our development costs.
	An element of our business strategy is to pursue, as resources permit, the research and development of a range of product candidates for a variety of indications. This is intended to allow us to diversify the risks associated with our research and development expenditures. To the extent we are unable to maintain a broad range of product candidates, our dependence on the success of one or a few product candidates would increase.
	As a result of the uncertainties discussed above, among others, we are unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our research and development projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business. Our estimated future capital requirements are uncertain and could change materially as a result of many factors, including the progress of our research, development, clinical, manufacturing, and commercialization activities. However we believe our current cash and investments and committed and expected revenues from our collaborators and strategic alliances and cash from our recently completed financings are expected to be sufficient to continue our current research, development and collaborative activities into the foreseeable future.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	(a) USE OF ESTIMATES
	The preparation of financial statements, in conformity with U.S. generally accepted accounting principles, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, and revenues and expenses during the period. Critical accounting policies involved in applying our accounting policies are those that require management to make assumptions about matters that are highly uncertain at the time the accounting estimate was made and those for which different estimates reasonably could have been used for the current period. Critical accounting estimates are also those which are reasonably likely to change from period to period, and would have a material impact on the presentation of our financial condition, changes in financial condition or results of operations. Our most critical accounting estimates relate to accounting policies for strategic alliances and research contract revenues, research and development activities, and stock-based compensation. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances. Actual results could differ from these estimates.
	(b) CASH AND CASH EQUIVALENTS
	Cash equivalents consist of highly liquid debt instruments, time deposits, and money market funds with original maturities of three months or less.
	(c) INVESTMENTS
	Our investments consist primarily of corporate stock and bonds, government agency bonds, and commercial paper. These investments are classified as available-for-sale securities, which are carried at fair value, with the unrealized holding gains and losses reported as a separate component of accumulated other comprehensive income (loss) until realized. Realized gains and losses from the sale of available-for-sale securities are determined on a specific-identification basis.
	A decline in the market value of any available-for-sale security below cost that is deemed to be other-than-temporary results in a reduction in carrying amount to fair value. The impairment is charged to earnings and a new cost basis for the security is established. To determine whether impairment is other-than-temporary, we consider whether we have the ability and intent to hold the investment until a market price recovery and consider whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary. Evidence considered in this assessment includes the reasons for the impairment, the severity and duration of the impairment, changes in value subsequent to year-end, forecasted performance of the investee, and the general market condition in the geographic area or industry the investee operates. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the effective interest method. Dividend and interest income are recognized when earned.
	(d) FAIR VALUE OF FINANCIAL INSTRUMENTS
	The carrying amounts of our financial instruments, as reflected in the accompanying balance sheets, approximate fair value. Financial instruments consist of cash and cash equivalents, investments, accounts receivable, and accounts payable.
	(e) PROPERTY AND EQUIPMENT
	Property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of assets, which are generally three to five years for equipment and seven years for furniture and fixtures. Leased property meeting certain criteria is capitalized at the lower of the present value of the future minimum lease payments or fair value at the inception of the lease. Amortization of capitalized leased assets is computed on a straight-line basis over the shorter of the lease term or estimated useful life of the asset. We incur maintenance costs with respect to some of our major equipment. Repair and maintenance costs are expensed as incurred.
	(f) REVENUE RECOGNITION
	Revenue is recognized when all four of the following criteria are met (i) a contract is executed, (ii) the contract price is fixed and determinable, (iii) delivery of the services or products has occurred, and (iv) collectability of the contract amounts is considered probable.
	Our collaborative research and development agreements provide for upfront license fees, research payments, and/or substantive milestone payments. Upfront non-refundable fees associated with license and development agreements where we have continuing involvement in the agreement are recorded as deferred revenue and recognized over the estimated service period. If the estimated service period is subsequently modified, the period over which the upfront fee is recognized is modified accordingly on a prospective basis. Non-refundable research and development fees for which no future performance obligations exist are recognized when collection is assured. Substantive milestone payments are considered performance payments and are recognized upon achievement of the milestone if all of the following criteria are met: (i) achievement of the milestone involves a degree of risk and was not reasonably assured at the inception of the arrangement; (ii) substantive effort is involved in achieving the milestone; and (iii) the amount of the milestone payment is reasonable in relation to all of the deliverables and payment terms within the arrangement. Determination of whether a milestone meets the aforementioned conditions involves the judgment of management.
	Research and development revenue from cost-reimbursement and cost-plus fixed-fee agreements is recognized as earned based on the performance requirements of the contract. Revisions in revenues, cost, and billing factors, such as indirect rate estimates, are accounted for in the period of change. Reimbursable costs under such contracts are subject to audit and retroactive adjustment. Contract revenues and accounts receivable reported in the financial statements are recorded at the amount expected to be received. Contract revenues are adjusted to actual upon final audit and retroactive adjustment. Estimated contractual allowances are provided based on management’s evaluation of current contract terms and past experience with disallowed costs and reimbursement levels. Payments received in advance of work performed are recorded as deferred revenue.
	Research and development revenue from fixed-price best efforts arrangements is recognized as earned based on the performance requirements of the contract. Revenue under these arrangements is recognized when delivery to and acceptance by the customer has been received. During the period of performance, recoverable contract costs are accumulated on the balance sheet in other current assets, but no revenue or profit is recorded prior to customer acceptance of the contractually stated deliverables. Recoverable contract costs that are accumulated on the balance sheet include all direct costs associated with the arrangement and an allocation of indirect costs. Payments received in advance of customer acceptance are recorded as deferred revenue. Once customer acceptance has been received, revenue and recoverable contract costs are recognized. Over the course of the arrangement, we routinely evaluate whether revenue and profitability should be recognized in the current period. Any known or probable losses on projects are charged to operations in the period in which such losses are determined.
	(g) RESEARCH AND DEVELOPMENT
	Research and development costs are charged to operations as incurred. Advance payments to acquire goods or pay for services that will be consumed or performed in a future period in conducting research and development activities are recorded as an asset when the advance payments are made. Capitalized amounts are recognized as expense when the research and development activities are performed; that is, when the goods without alternative future use are acquired or the service is rendered.
	Research and development costs include internal research and development expenditures (such as salaries and benefits, raw materials, supplies, and allocated facility expenses), contracted services (such as sponsored research, consulting, manufacture of drug supply, and testing services of proprietary research) and development activities and similar expenses associated with collaborative research agreements. These costs are expensed as incurred.
	(h) INCOME TAXES
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We recognize the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. We include any interest or penalties incurred in connection with income taxes as part of other expense.
	We have significant net operating loss carryforwards to potentially reduce future federal and state taxable income, and research and experimentation tax credit carryforwards available to potentially offset future federal income taxes. Due to the Company’s prior equity transactions, the Company’s net operating loss and research and experimentation credit carryforwards may expire unutilized due to changes in our ownership as defined within Section 382 of the Internal Revenue Code.
	The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making that assessment. We recorded a full valuation allowance against all estimated net deferred tax assets at December 31, 2013 and 2012.
	(i) NET LOSS PER SHARE
	Basic earnings per share is computed based upon the net loss available to common stock stockholders divided by the weighted average number of common stock shares outstanding during the period. The dilutive effect of common stock equivalents is included in the calculation of diluted earnings per share only when the effect of the inclusion would be dilutive. For the years ended December 31, 2013 and 2012 approximately 1.6 million and 0.7 million common stock equivalent shares associated with our stock option plans and unvested restricted shares and approximately 1.1 million and 1.4 million stock equivalent shares associated with our warrants, respectively, were excluded from the denominator in the diluted loss per share calculation as their inclusion would have been antidilutive.
	(j) COMPREHENSIVE INCOME (LOSS)
	Comprehensive income (loss) consists of net loss and unrealized holding gains and losses from available-for-sale securities.
	(k) STOCK-BASED COMPENSATION
	We use the modified prospective method to account for stock-based compensation. Under this method, we measure stock-based compensation expense based on the grant date fair value of the awards which is then recognized over the period during which service is required to be provided. We estimate grant date fair value using the Black-Scholes option-pricing model. Stock-based compensation cost that has been included in expense from continuing operations amounted to $0.9 million and $1.3 million for the years ended December 31, 2013 and 2012, respectively.
	(l) LONG-LIVED ASSETS
	Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset be tested for possible impairment, we first compare undiscounted cash flows expected to be generated by an asset to the carrying value of the asset. If the carrying value of the long-lived asset is not recoverable on an undiscounted cash flow basis, impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values, and third party independent appraisals, as necessary.
	(m) COMMITMENTS AND CONTINGENCIES
	Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.
	(n) RECENT ACCOUNTING PRONOUNCEMENTS
	In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (Topic 220). The standard requires that companies present either in a single note or parenthetically on the face of the financial statements, the effect of significant amounts reclassified from each component of accumulated other comprehensive income based on its source and the income statement line items affected by the reclassification. The Company’s adoption of the provisions of this guidance on January 1, 2013 did not have a material impact on our financial position, results of operations, or cash flows.
	There are no other new accounting pronouncements issued but not effective until after December 31, 2013 that are expected to have a significant effect on our financial position or results of operations.
	(o) RECLASSIFICATIONS
	We have made certain reclassifications to prior year accounts to conform to the 2013 presentation.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
FAIR VALUE MEASUREMENTS	'
	(3) FAIR VALUE MEASUREMENTS
	For assets and liabilities measured at fair value we utilize FASB Accounting Standards Codification (ASC) Section 820 “Fair Value Measurements and Disclosures” (ASC 820) that defines fair value and establishes a framework for fair value measurements. This standard establishes a three-level hierarchy for disclosure of fair value measurements. The hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels of inputs used to measure fair value are as follows:
		⋅	Level 1 — Quoted prices in active markets for identical assets or liabilities;
		⋅	Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable (e.g. interest rates, yield curves, volatilities and default rates, among others) or can be corroborated by observable market data; and
		⋅	Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies, and similar techniques that use significant unobservable inputs.
	The following table presents information about assets recorded at fair value on a recurring basis on the Balance Sheet at December 31, 2013:
	(In thousands)		Total Carrying Value		Quoted Prices in Active Markets for Identical		Significant Other
			on the Balance Sheet		Assets/Liabilities (Level 1)		Observable Inputs
							(Level 2)
	Assets:
	Cash and cash equivalents		$	5,249	$	5,249	$	—
	Corporate notes and bonds			303		—		303
	U.S. Government and agency securities			503		—		503
	Equity Securities			50		50		—
	Total assets at fair value		$	6,105	$	5,299	$	806
	The following table presents information about assets and liabilities recorded at fair value on a recurring basis on the Balance Sheet at December 31, 2012:
	(In thousands)		Total Carrying		Quoted Prices in Active Markets for		Significant Other
			Value on the		Identical Assets/Liabilities (Level 1)		Observable Inputs
			Balance Sheet				(Level 2)
	Assets:
	Cash and cash equivalents		$	4,150	$	4,150	$	—
	Corporate notes and bonds			6,871		—		6,871
	U.S. Government and agency securities			4,189		—		4,189
	Equity Securities			45		45		—
	Total assets at fair value		$	15,255	$	4,195	$	11,060
	We determine fair value for our investments with Level 1 inputs through quoted market prices and have classified them as available-for-sale. Our Level 2 investments consist of corporate notes and bonds and U.S. government agency  securities with maturities of less than twelve months.
	We review all investments for other-than-temporary impairment at least quarterly or as indicators of impairment exist. Indicators of impairment include the duration and severity of the decline in fair value as well as the intent and ability to hold the investment to allow for a recovery in the market value of the investment. In addition, we consider qualitative factors that include, but are not limited to: (i) the financial condition and business plans of the investee including its future earnings potential; (ii) the investee’s credit rating; and (iii) the current and expected market and industry conditions in which the investee operates. If a decline in the fair value of an investment is deemed by management to be other-than-temporary, we write down the cost basis of the investment to fair value, and the amount of the write down is included in net earnings. Such a determination is dependent on the facts and circumstances relating to each investment. We have determined there have been no such impairments in 2013 or 2012.
	All unrealized holding gains or losses related to our investments in marketable securities are reflected in our statements of operations and comprehensive loss.
	A summary of marketable securities is shown below:
					Gross Unrealized
			Amortized Cost		Gains		Losses		Fair Value
			(in thousands)
	31-Dec-13
	Marketable securities
	Corporate and agency notes and corporate stock		$	878	$	—	$	-22	$	856
	Total marketable securities		$	878	$	—	$	-22	$	856
	31-Dec-12
	Marketable securities
	Corporate and agency notes and corporate stock		$	11,132	$	—	$	-27	$	11,105
	Total marketable securities		$	11,132	$	—	$	-27	$	11,105

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
PROPERTY AND EQUIPMENT	'
	(4) PROPERTY AND EQUIPMENT
	Property and equipment consists of the following at December 31:
		2013		2012
		(in thousands)
	Equipment	$	5,777	$	9,750
	Leasehold improvements		6,543		6,563
	Furniture and fixtures		437		437
			12,757		16,750
	Less accumulated depreciation and amortization		-12,243		-15,945
		$	514	$	805
	Depreciation and amortization expense related to property and equipment was $0.2 million for the years ended December 31, 2013 and 2012, respectively. In November 2013, we sold laboratory and other long-lived assets that were no longer needed for our current operating strategy. We recognized a gain of approximately $0.3 million on the sales. We also evaluated certain of our long-lived assets and determined that approximately $0.2 million of these assets were impaired during the second quarter of 2013. Gains and losses associated with the sale of long-lived equipment and the impairment of long-lived assets have been recorded within general and administrative expense, as applicable. Additionally, non-capital laboratory equipment was sold for net proceeds of approximately $0.3 million. Gains associated with the sale of non-capital laboratory supplies and equipment has been recorded as Other Income.

ACCRUED_EXPENSES_AND_OTHER

ACCRUED EXPENSES AND OTHER	12 Months Ended
	Dec. 31, 2013
Other Liabilities Disclosure [Abstract]	'
ACCRUED EXPENSES AND OTHER	'
	(5) ACCRUED EXPENSES AND OTHER
	Accrued expenses consist of the following at December 31:
		2013		2012
		(in thousands)
	Payroll, compensation, and benefits	$	905	$	1,490
	Professional fees		534		523
	Other		157		174
	Total accrued expenses	$	1,596	$	2,187

STRATEGIC_ALLIANCES_AND_RESEAR

STRATEGIC ALLIANCES AND RESEARCH CONTRACTS	12 Months Ended
	Dec. 31, 2013
Strategic Alliances And Research Contracts [Abstract]	'
STRATEGIC ALLIANCES AND RESEARCH CONTRACTS	'
	(6) STRATEGIC ALLIANCES AND RESEARCH CONTRACTS
	We have established collaborations and research contracts with pharmaceutical and biotechnology companies and governmental agencies to enhance our ability to discover, evaluate, develop, and commercialize multiple product opportunities. Revenue earned under these contracts is summarized as follows:
		2013		2012
		(in thousands)
	Hearing Program	$	924	$	4,435
	Foot and Mouth Disease Program		641		2,344
	Vaccine Research Center		157		490
	Malaria Program		1,571		359
	Other strategic alliances and research grants		389		1,725
		$	3,682	$	9,353
	(a) NOVARTIS
	In January 2010, we signed a research collaboration and license agreement (the Agreement) with Novartis to discover and develop novel treatments for hearing loss and balance disorders. Under terms of the Agreement, we licensed the world-wide rights to our preclinical hearing loss and balance disorders program to Novartis. We received a $5.0 million non-refundable upfront license fee and Novartis purchased $2.0 million of our common stock. The common stock was recorded at fair value of $3.3 million on the date of issuance. The upfront non-refundable fee was recognized ratably over the initial term of the two-year research and collaboration term of the Agreement. Revenue recognized from the non-refundable upfront license fee was $3.7 million by the end of the initial Agreement due to the pricing agreement associated with the sale of our common stock. In addition, we receive funding from Novartis for a research program focused on developing additional adenovectors for hearing loss. During the years ended December 31, 2013 and 2012 we recognized $0 and $78,000, respectively, of the upfront payment and $0.4 million and $0.8 million, respectively, for research performed under this Agreement.
	Under the Agreement, we are eligible to receive milestones payments of up to $206.6 million; including up to $0.6 million for the achievement of preclinical development activities, up to $26.0 million for the achievement of clinical milestones including (non-rejection of an IND with respect to a covered product, the first patient visit in Phase I, Phase IIb and Phase III clinical trials), up to $45.0 million for the receipt of regulatory approvals and up to $135.0 million for sales-based milestones. During each of the years ended December 31, 2011 and 2010, we recognized $0.3 million of milestone payments as a result of the successful completion of preclinical development activities. In 2012 and 2013, there were no milestone payments received. In February 2014, we achieved the third milestone in the collaboration with Novartis. The $2.0 million milestone was triggered by the non-rejection by the FDA of the IND filed by Novartis for CGF166.
	In August 2010, we signed an agreement for the supply of services relating to development materials with Novartis, related to our collaboration in hearing loss and balance disorders. Under this agreement, valued at $14.9 million, we agreed to manufacture clinical trial material for up to two lead candidates. During the years ended December 31, 2013 and 2012 we recognized $0.4 million and $3.4 million, respectively, for services performed under this new agreement.
	In both January 2012 and January 2013, we announced that we had extended our Research Collaboration and License Agreement with Novartis. Under the extensions, Novartis will fund research at GenVec through January 2014 to support this program.
	In February 2014, we achieved the third milestone in the collaboration with Novartis. The $2.0 million milestone was triggered by the non-rejection of the IND application filed by Novartis with the FDA. As of February 28, 2014, milestones available under the Agreement include $24.0 million of additional clinical milestones, $45.0 million in regulatory milestones, and $135.0 million of sales-based milestones. We are also entitled to royalties on future sales.
	(b) U.S. DEPARTMENT OF HOMELAND SECURITY (DHS)
	In January 2007, we signed a three-year agreement with the DHS, for the development of a vaccine candidate against foot-and-mouth disease (FMD) for livestock, under which we received $6 million in program funding for the first year and had the potential to receive up to $15.1 million in total if annual renewal options under the contract were exercised. Modifications to this agreement have brought the total value of the program up to approximately $20.8 million. During the years ended December 31, 2013 and 2012 we recognized $3,000 and $0.6 million for services performed under this new agreement, respectively. As of December 31, 2013, $20.7 million in revenue has been recognized under this contract since inception. Work under this agreement was completed in 2013.
	In February 2010, we signed a contract with the DHS to continue the development of adenovector-based vaccines against FMD. Under this contract, GenVec was to receive $3.8 million in program funding the first year and an additional $0.7 million if DHS exercises its renewal option under the contract. Under this contract, we were to use our adenovector technology to develop additional FMD-serotype candidate vaccines and also explore methods to increase the potency and simplify the production process of adenovector-based FMD vaccines. In June 2010, the DHS exercised its renewal option for 2011 funding under this agreement for $0.7 million. During the years ended December 31, 2013 and 2012, we recognized $0.6 million and $1.7 million, respectively, for services performed under this agreement. As of December 31, 2013, $5.1 million in revenue has been recognized under this contract since inception. Work under this agreement will be completed in 2014.
	(c) VACCINE RESEARCH CENTER
	In November 2009, we entered into a contract with SAIC-Frederick, Inc., for the development of influenza and HIV vaccines pursuant to their prime grant from the National Cancer Institute. Work under this contract includes generation of HIV vaccine candidates, generation of a universal flu vaccine, process and assay development for manufacture of vaccine candidates for clinical testing, and continued support of the HIV vaccine candidates currently in clinical testing. This four-year contract has a total value of over $22 million if all options are exercised. Revenues of $157,000 and $0.4 million were recognized under this contract for the years ended December 31, 2013 and 2012. As of December 31, 2013, $5.8 million in revenue has been recognized under this contract since inception. Work under this agreement was completed in 2013.
	In July 2009, we received a grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIAID), valued at approximately $600,000 to identify new antigens for malaria vaccine development. We recognized $8,000 and $121,000 in revenue for the years ended December 31, 2013 and 2012.
	In March 2012, we received a grant from the NIAID, valued at approximately $600,000 to identify novel highly protective antigens for malaria vaccine development. We recognized $133,000 and $94,000 in revenue for the years ended December 31, 2013 and 2012.
	(d) OTHER STRATEGIC ALLIANCES AND RESEARCH GRANTS
	In October 2012, we signed an agreement worth approximately $3.5 million with the NMRC to further support malaria vaccine development. Under the terms of the agreement, we were responsible for producing clinical supplies of its malaria vaccine, which utilized our novel, proprietary technology. NMRC plans to use this clinical material to assess the safety and efficacy of these next-generation vectored vaccines using the clinical challenge model developed by NMRC and the Walter Reed Army Institute of Research (WRAIR) malaria vaccine programs, which now are unified as the U.S. Military Malaria Vaccine Program (USMMVP). Under the agreement, we retained the right to commercialize this novel technology. We recognized $1.4 million in revenue under this contract in 2013 and no revenue in 2012. In July 2013 we entered into a modification with the NMRC to terminate contractual obligations under this agreement.
	In May 2012, we received Phase 1 SBIR grant from the NIH to support the Company’s Respiratory Syncytial Virus (RSV) vaccine program. The SBIR grant, valued at approximately $590,000 provides funding to further understand the impact of maternal immunity against RSV on the generation of a protective immune response in newborns. We recognized $122,000 and $109,000 in revenue for the years ended December 31, 2013 and 2012.
	In August 2009, we received a Phase 2 SBIR grant, valued at $2.5 million, from the NIAID to support the development of our cell line and vector production technology. Revenues of $0.3 million and $1.3 million were recognized under this grant for the years ended December 31, 2013 and 2012. Revenue recognized under this grant amounted to $2.3 million through December 31, 2013. Work under this grant was completed in 2013.
	We have entered into other research grants with the government, primarily the NIH, and recognized revenue under other collaborations during 2013. Revenue recognized under these research grants totaled $0.2 million and $0.8 million in revenue for the years ended December 31, 2013 and 2012.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	(7) COMMITMENTS AND CONTINGENCIES
	(a) LEASE AGREEMENTS
	We have a non-cancelable operating lease for our new facility in Gaithersburg, MD through October 31, 2019. We also have a non-cancelable operating lease for our old facility in Gaithersburg, MD through October 31, 2014. Rent expense under all operating leases was approximately $0.8 million for each of the years ended December 31, 2013 and 2012.
	Future minimum lease payments under our non-cancelable operating leases are as follows (in thousands):
	2014	$	1,168
	2015		246
	2016		124
	2017		128
	2018		131
	2019		113
	(b) LICENSE AGREEMENT
	In November 2001, we entered into an exclusive, worldwide license agreement with Baylor College of Medicine for the rights related to the Atoh1 gene. Under the terms of the license agreement, we agreed to pay a non-refundable initial license fee of $50,000 at the time of execution of the license agreement and we also agreed to pay a minimum annual license maintenance fee, a percentage of product royalties, and milestone payments based on our achievement of certain clinical and regulatory related milestones for these rights. Our ability to meet the milestones is dependent on a number of factors including final approvals by regulatory agencies and the continued enforceability of patent claims.
	(c) LEGAL PROCEEDINGS
	On February 3, 2012, a putative class action lawsuit captioned Satish Shah v. GenVec, Inc., et al. Civil Action. No. 8:12 CV-00341-DKC was commenced in the United States District Court for the District of Maryland against the Company, Paul H. Fischer, Douglas J. Swirsky, and Mark O. Thornton. Following appointment of a Lead Plaintiff group in April 2012, Lead Plaintiffs filed a pleading titled Amended Class Action Complaint for Violations of the Federal Securities Laws on July 6, 2012 (the Amended Complaint). In the Amended Complaint, Lead Plaintiffs asserted claims, purportedly on behalf of a class of persons who had purchased or acquired Company common stock between March 12, 2009 and March 30, 2010 (the Class Period), that the Company and the individual defendants had violated Section 10(b) of the Securities Exchange Act of 1934 (the Exchange Act), Rule 10b-5 promulgated thereunder, and Section 20(a) of the Exchange Act. Lead Plaintiffs alleged generally that defendants had made materially false or misleading statements or omissions concerning the prospects for the Company’s leading product candidate at the time, TNFerade, and the outcome of the then-ongoing clinical trial for TNFerade. Lead Plaintiffs alleged that these misrepresentations resulted in the Company’s common stock trading at artificially inflated prices throughout the Class Period. Lead Plaintiffs sought unspecified damages. On September 4, 2012, the Company and the individual defendants moved to dismiss the Amended Complaint in its entirety for failure to state a claim upon which relief can be granted. On September 20, 2013, the Court granted this motion and dismissed the case in its entirety and with prejudice. Lead Plaintiffs did not file an appeal.
	On March 12, 2012, a putative shareholder derivative action was commenced in the United States District Court for the District of Maryland against certain current and former members of our Board of Directors and the Company as a nominal defendant. The case is styled Garnitschnig v. Horovitz, et al. and generally arose out of the matters alleged to underlie the securities action. The plaintiff, who purported to bring the action derivatively on behalf of the Company, alleged that the defendants violated their fiduciary duties, wasted corporate assets and were unjustly enriched by the receipt of compensation while serving as our directors. More particularly, the plaintiff’s Complaint alleged that as a result of the defendants’ failure of oversight, we disseminated misleading public statements and improperly continued with a clinical trial. While the Garnitschnig action did not seek a monetary recovery against the Company, plaintiff sought, among other things, an unspecified award of damages against the defendants, an order directing us to make certain changes to our corporate governance and oversight procedures, disgorgement by the defendants of compensation and an award of attorneys’ fees. Pursuant to the Court’s order dated April 5, 2013, the Garnitschnig case was stayed pending a decision on the motions to dismiss filed in the Shah action. On October 2, 2013, the parties entered into a stipulation confirming that the stay of the Garnitschnig action was lifted and providing that, if the plaintiff elected to continue with the action, he would file an Amended Complaint on or before November 26, 2013.
	On November 1, 2013, the plaintiff in the Garnitschnig action filed an Amended Verified Shareholder Derivative and Class Action Complaint (the “Amended Complaint”) that supersedes the previous Complaint and now asserts claims for breach of fiduciary duty, unjust enrichment, waste of corporate assets, and alleged violations of the duty of candor. The plaintiff, who now purports to bring the Amended Complaint both derivatively and as a shareholder class action, alleges that certain current and former members of the Board of Directors exceeded their authority under the Company’s 2011 Omnibus Incentive Plan (the “2011 Plan”) by exceeding certain limits applicable to both stock options and restricted stock. The Amended Complaint further alleges that Company’s Proxy Statement is materially false and misleading for failing to disclose the alleged violations of the 2011 Plan. The Amended Complaint seeks, among other things, an unspecified amount of damages.
	On November 1, 2013, the plaintiff in the Garnitschnig action also filed a motion for preliminary injunction seeking to postpone the Company's 2013 annual meeting unless and until certain disclosures were made to the Company's shareholders regarding the 2011 Plan. On November 20, 2013, the Court denied that motion in its entirety. Defendants then filed motions to dismiss the Amended Complaint on January 27, 2014. Those motions have not yet been fully briefed and remain pending. The Company intends to vigorously defend this action. We also are informed that the individual defendants deny the material allegations of the Garnitschnig action and intend to continue vigorously defending the case.
	(d) RESTRUCTURING
	On September 25, 2012, we eliminated 23 positions, or approximately 30% of our workforce in order to reduce our operating costs and conserve capital. As a result, approximately $0.7 million of severance costs was incurred in the third quarter of 2012, all of which has been paid as of September 30, 2013.
	On February 7, 2013, we eliminated nine positions as part of our efforts to lower operating costs to conserve capital. The Company incurred $0.2 million of expenses due to the position eliminations with approximately $85,000 paid in the first quarter of 2013 and $90,000 in the second quarter of 2013.
	On June 28, 2013, we announced the termination of 30 of our then-remaining 41 employees. The Company incurred $0.3 million of expenses in the second quarter of 2013 due to the position eliminations, which resulted in cash expenditures of that amount in the third quarter.
	On September 3, 2013, we announced that Cynthia Collins, our then President and Chief Executive Officer, had departed the Company and resigned as a member of its Board of Directors. Douglas J. Swirsky, who had served as GenVec’s Senior Vice President and Chief Financial Officer since 2006, was named as the Company’s President and Chief Executive Officer and appointed to the Company’s Board of Directors. The Company incurred $1.0 million of expense in the third quarter of 2013 due to the departure of Ms. Collins that will be paid out over 18 months, in accordance with her employment agreement.
	Costs associated with the elimination of positions have been recorded as a general and administrative personnel cost.
	At December 31, 2013 and 2012, liabilities of approximately $817,000 and $469,000, respectively, remain in accrued expenses for the unpaid portion of the severance costs.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
STOCKHOLDERSb EQUITY	'
	(8) STOCKHOLDERS’ EQUITY
	(a) CAPITAL STOCK
	In January 2014, we filed a $75.0 million shelf registration statement on Form S-3 (the 2014 shelf registration statement), with the Securities and Exchange Commission. The 2014 shelf registration statement was declared effective February 11, 2014 and allows us to obtain financing through the issuance of any combination of common stock, preferred stock or warrants. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. As of March 24, 2014, pursuant to the Equity Distribution Agreement and the Registered Direct Offering described below we have sold approximately $11.6 million of securities since February 11, 2014.
	On February 11, 2014, we entered into an Equity Distribution Agreement (the EDA) with Roth Capital Partners, LLC (Roth Capital Partners), pursuant to which we may sell from time to time up to $10.0 million of shares of our common stock, par value $0.001 per share, through Roth Capital Partners (the ATM Offering). Sales of shares in the ATM Offering, if any, may be made by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act of 1933, as amended, including without limitation directly on the NASDAQ Capital Market, or any other existing trading market for the shares or through a market maker, or, if agreed by the Company and Roth Capital Partners, by any other method permitted by law, including but not limited to in negotiated transactions. The ATM Offering is being made pursuant to the 2014 shelf registration statement. We intend to use the net proceeds from the sale of shares in the ATM Offering, if any, for operating costs, working capital and general corporate purposes. At the time of the registered direct offering described immediately below, we suspended the ATM Offering. We will continue to evaluate whether to resume the ATM offering in the future. As of March 18, 2014, we had sold 721,677 shares in the ATM Offering for gross proceeds of approximately $2.6 million.
	On March 18, 2014, we sold 2,870,000 shares of our common stock in a registered direct offering pursuant to the 2014 shelf registration statement (the Registered Direct Offering), at a price of $3.15 per share, resulting in net proceeds of approximately $8.4 million. We intend to use the net proceeds from the sale of shares in the Registered Direct Offering for operating costs, working capital and general corporate purposes.
	In September 2001, our Board of Directors of the Company adopted a Stockholders Rights Plan, and in connection therewith declared a dividend which was issued on September 28, 2001 of one preferred stock purchase right (a Right) for each share of common stock outstanding. The Rights would become exercisable only if a person or group acquired beneficial ownership of 20 percent or more of the outstanding common stock of GenVec (an Acquiring Person), or announced the intention to commence a tender or exchange offer the consummation of which would result in that person or group becoming an Acquiring Person. The Stockholder Rights Plan expired in September 2011.
	In August 2011, the Company’s Board of Directors adopted a new Stockholder Rights Agreement between the Company and American Stock Transfer & Trust Company, LLC, as rights agent, to be effective on September 7, 2011 upon expiration of the prior Stockholder Rights Agreement. The new Stockholder Rights Agreement was not adopted in response to any specific effort to acquire control of the Company. In connection with the adoption of the new Stockholder Rights Agreement, the Company’s Board of Directors declared a dividend of one preferred stock purchase right, or Right, for each outstanding share of common stock to stockholders of record as of the close of business on September 7, 2011. Initially, the Rights will be represented by GenVec's common stock certificates or book entry notations, will not be traded separately from the common stock and will not be exercisable. In the event that any person acquires beneficial ownership of 20% or more of the outstanding shares of GenVec's common stock, or upon the occurrence of certain other events, each holder of a Right, other than the acquirer, would be entitled to receive, upon payment of the purchase price, which is initially set at $32 per Right, a number of shares of GenVec common stock having a value equal to two times such purchase price. The Company’s Board of Directors is entitled to redeem the Rights at $0.001 per right at any time before a person or group has acquired 20% or more of the Company’s common stock. The Rights will expire on September 7, 2021, subject to the Company’s right to extend such date, unless earlier redeemed or exchanged by the Company or terminated. The Rights will at no time have any voting rights. The Company has authorized 30,000 shares of Series B Junior Participating Preferred Stock in connection with the adoption of the new Stockholder Rights Agreement. There was no Series B Junior Participating Preferred Stock issued or outstanding as of December 31, 2013 or December 31, 2012.
	In addition to the common stock reflected on our balance sheets, the following items are reflected in the capital accounts as of December 31, 2013 and 2012:
		⋅	4,400,000 shares of $0.001 par value preferred stock have been authorized; none are issued or outstanding.
		⋅	600,000 shares of $0.001 par value Series A junior participating preferred stock have been authorized in connection with the preferred stock purchase rights referred to above; none are issued or outstanding.
	(b) STOCK-BASED COMPENSATION
	Stock Incentive Plans
	Our stockholders approved the 2011 Omnibus Incentive Plan (2011 Plan) in June 2011. In July 2012 at the Company’s 2012 Annual Meeting of Stockholders, the stockholders of GenVec, Inc. (the “Company”) approved an amendment to the GenVec, Inc. Omnibus Incentive Plan (the “2011 Plan”) to increase the number of shares of common stock that are available to be issued through grants or awards made thereunder or through the exercise of options granted thereunder by 640,000 shares. On September 3, 2013, the Board of Directors of the Company acted to award shares of restricted stock pursuant to the 2011 Plan and thereby amended the Plan to provide that the limitation in Section 6.2(b) of the 2011 Plan on the maximum number of shares of stock that may be granted under the 2011 Plan, other than pursuant to Options or SARs (as those terms are defined in the 2011 Plan), in a calendar year was increased to 200,000 shares for purposes of those awards. In November 2013 at the Company’s 2013 Annual Meeting of Stockholders, the stockholders of the Company approved an amendment to the 2011 Plan to increase the number of shares of common stock that are available to be issued through grants or awards made thereunder or through the exercise of options granted thereunder by 500,000 shares. At December 31, 2013 there are 1,035,125 shares available for future issuance and 1,345,542 outstanding options and 730,000 outstanding restricted stock awards under the 2011 Plan, CEO incentive, and 2002 Plan. Options outstanding under the 2011 Plan at December 31, 2013 expire through 2023. Restricted stock awards generally vest over a two-year term, with 100% vesting two years after issuance. In 2013, no restricted stock awards vested.
	Stock options granted under the 2011 Plan generally have a contractual term of 10 years. and will vest and become exercisable as to one-eight (1/8th) of the shares of common stock covered by the option on the six month anniversary of the grant date and, on the first day of each month thereafter the option will vest and become exercisable as to an additional one-forty-eighth (1/48th) of the shares of common stock covered by the option until the option is fully exercisable.  The Compensation Committee administers the 2011 Plan, approves the individuals to whom options, restricted stock, or other awards will be granted, and determines the terms of the awards, including the number of shares granted and exercise price of each option.
	The 2011 Plan replaces the 2002 Stock Incentive Plan (2002 Plan), which was approved in June 2002 as the replacement for the 1993 Stock Incentive Plan (1993 Plan). There are 371,876 outstanding options and no outstanding restricted stock awards under the 2002 Plan at December 31, 2013. Options outstanding under the 2002 Plan at December 31, 2013 expire through 2021. Restricted stock awards under the 2002 Plan generally vest over a three-year term, with 50% vesting two years after issuance and 50% vesting three years after issuance. In 2012, all 11,750 remaining outstanding restricted stock awards issued under the 2002 Plan vested on October 14, 2012.
	In May 2012, the Company granted an Inducement Award to purchase shares of common stock to our then President and Chief Executive Officer pursuant to a CEO inducement award agreement. The Inducement Award allows for the purchase of up to 250,000 shares of common stock at an exercise price per share equal to $2.54. The option has a ten-year term and will vest and become exercisable as to one-eighth ( 1/8th) of the shares of common stock covered by the option on the six month anniversary of the grant date and, on the first day of each month thereafter the option will vest and become exercisable as to an additional one-forty-eighth ( 1/48th) of the shares of common stock covered by the option until the option is fully exercisable. When Ms. Collins departed the Company she forfeited her unvested shares as of September 3, 2013. There are 83,333 outstanding options awards under the CEO inducement plan at December 31, 2013.
	Stock-Based Compensation Expense
	The following table summarizes stock-based compensation expense related to employee stock options for the years ended December 31, 2013 and 2012, which was allocated as follows:
			Years ended December 31,
			2013			2012
			(in thousands)
	Research and development		$	472		$	864
	General and administrative			408			415
			$	880		$	1,279
	We use the Black-Scholes pricing model to value stock options. The weighted-average estimated fair value of employee stock options granted during the 12 months ended December 31, 2013 and 2012 was calculated using the Black-Scholes model with the following weighted-average assumptions:
			2013				2012
	Weighted average risk-free interest rate			1.06	%			1.05	%
	Expected dividend yield			0	%			0	%
	Expected volatility			98.09	%			97.97	%
	Expected life (years)			6.1				6.3
	Weighted-average fair value of options granted		$	1.23			$	1.99
	The risk-free interest rate assumption is based upon various U.S. Treasury rates as of the date of the grants, ranging from 1.00 percent to 1.85 percent and 0.81 percent to 1.66 percent, respectively, for the years ended December 31, 2013 and 2012. The dividend yield is based on the assumption that we are not expected to declare a dividend over the life of the options. The volatility assumption for 2013 and 2012 is based on the weighted average volatility for the most recent one-year period as well as the volatility over the expected life of 6.10 and 6.30, respectively. The expected life of employee stock options represents the weighted average combining the actual life of the options that have already been exercised or cancelled with the expected life of all outstanding options. The expected life of outstanding options is calculated assuming the options will be exercised at the midpoint of the vesting date and the full contractual term.
	The Company estimates forfeiture rates at the time of grant and revises these estimates, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based on the demographics of current option holders and standard probabilities of employee turnover. Stock-based compensation expense recognized in the statement of operations for the year ended December 31, 2013 and 2012 has been adjusted for actual forfeitures during the respective periods. We do not record tax-related effects on stock-based compensation given our historical and anticipated operating experience and offsetting changes in our valuation allowance which fully reserves against potential deferred tax assets.
	Stock Options
	The activity of the plans from December 31, 2011 to December 31, 2013 is as follows:
	(in thousands, except per share data)		Number of Shares Under Option			Weighted Average		Weighted Average			Aggregate
						Exercise Price		Contractual Life			Intrinsic Value
								(years)
	Outstanding at December			1,021			14.77
	31, 2011
	Granted			1,006			2.48
	Cancelled			-618			12.34
	Outstanding at December			1,409			7.06
	31, 2012
	Granted			676			1.57
	Exercised			—			—
	Forfeited			-551			2.29
	Cancelled			-188			13.55
	Stock options outstanding			1,346		$	5.35			7.6	$	306
	at December 31, 2013
	Vested or expected to vest			1,281		$	5.52			7.5	$	271
	at December 31, 2013
	Exercisable at December			919		$	6.88			7	$	77
	31, 2013
	Unrecognized stock-based compensation expense related to stock options was approximately $0.5 million as of December 31, 2013. This amount is expected to be expensed over a weighted average period of 2.5 years. There were no stock options exercised during the years ended December 31, 2013 or 2012.
	The following table summarizes information about our stock options outstanding at December 31, 2013:
			Outstanding								Exercisable
	Range of exercise prices		Number of shares			Weighted average remaining			Weighted average		Number of shares		Weighted average
						contractual life			exercise price				exercise price
		(number of shares in thousands)
	$0.00 – $10.00			1,126			8.3		$	2.53		701	$	2.86
	$10.01 – $20.00			124			3.2			15.82		124		15.82
	$20.01 – $30.00			83			5			23.57		81		23.59
$30.01 – $41.00			13			0.7			33.21		13		33.21
			1,346			7.6 years		$	5.35		919	$	6.88
As of December 31, 2013 options covering 919,224 shares were exercisable at $1.56 to $41.00 per share (average $6.88 per share) and options covering 1,035,125 shares remain available to be granted.
Restricted Stock Awards
In September 2013, the Company issued 730,000 restricted shares of common stock under the 2011 Plan. The following table summarizes the status of the Company’s unvested restricted stock as of December 31, 2013:
(in thousands, except per share data)		Number of Shares			Weighted Average Grant			Aggregate Intrinsic
					Date Fair Value			Value
Non-vested RSU's at December 31, 2011			20		$	7.9
Granted			—			—
Vested			-12			—
Forfeited			-8			—
Non-vested RSU's at December 31, 2012			—			—
Granted			730			0.27
Vested			—			—
Forfeited			—			—
Non-vested restricted stock units at			730		$	0.27		$	194
December 31, 2013
Expected to vest at December 31, 2013			582		$	0.27		$	155
Restricted stock awarded in 2013 vests 100% two years after the date of grant. The cost of the grant is charged to operations over the vesting period. Unrecognized stock-based compensation expense related to restricted stock units was approximately $0.2 million as of December 31, 2013. This amount is expected to be expensed over a weighted average period of 1.7 years.
(c) WARRANTS
Warrants to purchase common stock were granted to organizations and institutions in conjunction with certain licensing and funding activities. The warrants typically vest six-months after issuance. Outstanding warrants are summarized below (in thousands, except per share amounts):
Offering Date		Outstanding Warrants			Exercise Price			Expiration Date		Status
May-09			711,539		$	8.58			5/29/14		Exercisable
Feb-10			420,000		$	27.5			2/1/15		Exercisable
			1,131,539
On June 11, 2013, 220,383 warrants with an exercise price of $20.16 issued in June 2008 expired. There were no warrants exercised during the year ended December 31, 2013.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	(9) INCOME TAXES
	For the years ended December 31, 2013 and 2012 there is no provision for income taxes included in the statement of operations. We have incurred operating losses, but have not recorded an income tax benefit for 2013 and 2012 as we have recorded a valuation allowance against our net operating losses and other net deferred tax assets due to uncertainties related to the ability to realize these tax assets. A reconciliation of tax credits computed at the statutory federal tax rate (34%) on operating loss before income taxes to the actual income tax expense is as follows (in thousands):
		2013		2012
	Tax provision computed at the statutory rate	$	-3,406	$	-4,779
	State income taxes, net of federal income tax provision		-546		-765
	Book expenses not deductible for tax purposes		11		18
	Nondeductible compensation expense		185		277
	Expired net operating losses and other		1,662		17,305
	Change in valuation allowance for deferred tax assets		2,094		-12,056
	Income tax expense	$	—	$	—
	The Company provides for the recognition of deferred tax assets if realization of such assets is more likely than not. Based upon the weight of available evidence, which includes our historical operating performance and the reported accumulated net losses to date, we have provided a full valuation allowance against our deferred tax assets.
	Deferred income taxes reflect the net effects of net operating loss carryforwards and the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets are as follows (in thousands):
		2013		2012
	Net operating loss carryforwards	$	98,944	$	95,497
	Research and experimentation tax credit		14,226		14,568
	Property and equipment, principally due to differences in depreciation		-141		-151
	Accrued severance		266		102
	Deferred compensation expense		783		2,053
	Other		197		131
	Total deferred tax assets		114,275		112,200
	Valuation allowance		-114,275		-112,200
	Net deferred tax assets	$	—	$	—
	The difference reflected in the change in the valuation allowance as it appears in the analysis of deferred tax assets in comparison to the reconciliation of income tax expense is the result of the tax impact of other comprehensive income.
	At December 31, 2013, we have net operating loss carryforwards of approximately $250.8 million for federal income tax purposes which expire at various dates through 2032. We have research and experimentation tax credit carryforwards of $14.2 million at December 31, 2013 which will expire at various dates through 2032. During 2013, $0.3 million of research and experimentation tax credit expired.
	Our NOL and tax credit carryforwards may be significantly limited under Section 382 of the Internal Revenue Code (IRC). NOL and tax credit carryforwards are limited under Section 382 when there is a significant “ownership change” as defined in the IRC. The amount of US loss carryforward which can be used by the Company each year is limited due to changes in the Company’s ownership which occurred in 2006. Thus, a portion of the Company’s loss carryforward may expire unutilized.
	The limitation imposed by Section 382 would place an annual limitation on the amount of NOL and tax credit carryforwards that can be utilized. When we complete the necessary studies, the amount of NOL carryforwards available may be reduced significantly. However, since the valuation allowance fully reserves for all available carryforwards, the effect of the reduction would be offset by a reduction in the valuation allowance. Thus, the resolution of this matter would have no effect on the reported assets, liabilities, revenues, and expenses for the periods presented.
	As discussed in Note 2, we recognize the effect of income tax positions only if those positions are more likely than not of being sustained effective January 1, 2007. At December 31, 2013 and December 31, 2012, we had no gross unrecognized tax benefits. We do not expect any significant changes in unrecognized tax benefits over the next 12 months. In addition, we did not recognize any interest or penalties related to uncertain tax positions at December 31, 2013 and 2012.
	We file U.S. and state income tax returns in jurisdictions with varying statutes of limitations. The 2010 through 2012 tax years generally remain subject to examination by federal and most state tax authorities. In addition, we would remain open to examination for earlier years if we were to utilize net operating losses or tax credit carryforwards that originated prior to 2010.

QUARTERLY_RESULTS

QUARTERLY RESULTS	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
QUARTERLY RESULTS	'
	(10) QUARTERLY RESULTS (UNAUDITED)
	Our unaudited quarterly information is as follows:
	2013 (unaudited)	Q1		Q2		Q3		Q4
		(in thousands, except per share data)
	Revenue	$	1,207	$	748	$	1,582	$	145
	Operating Loss	$	-3,054	$	-3,131	$	-2,963	$	-1,146
	Net Loss	$	-3,045	$	-3,126	$	-2,961	$	-887
	Basic and Diluted Loss Per Share	$	-0.24	$	-0.24	$	-0.23	$	-0.07
	2012 (unaudited)	Q1		Q2		Q3		Q4
		(in thousands, except per share data)
	Revenue	$	3,164	$	2,540	$	2,128	$	1,521
	Operating Loss	$	-3,203	$	-3,673	$	-4,051	$	-3,170
	Net Loss	$	-3,194	$	-3,663	$	-4,039	$	-3,159
	Basic and Diluted Loss Per Share	$	-0.25	$	-0.28	$	-0.31	$	-0.24
	The loss per share was calculated for each three-month period on a stand-alone basis. As a result, the sum of the loss per share for the four quarters may not equal the loss per share for the respective 12-month period.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	(11) SUBSEQUENT EVENTS
	On January 23, 2014, we filed a $75.0 million shelf registration statement on Form S-3 (the 2014 shelf registration statement), with the Securities and Exchange Commission. The 2014 shelf registration statement was declared effective February 11, 2014 and allows us to obtain financing through the issuance of any combination of common stock, preferred stock or warrants.
	In February 2014, we achieved the third milestone in the collaboration with Novartis. The $2.0 million milestone was triggered by the non-rejection of the Investigational New Drug application filed by Novartis with the U.S. Food and Drug Administration. As of February 28, 2014, milestones available under the Agreement include $24.0 million of additional clinical milestones, $45.0 million in regulatory milestones, and $135.0 million of sales-based milestones. We are also entitled to royalties on future sales.
	On February 11, 2014, we entered into an Equity Distribution Agreement with Roth Capital Partners, LLC (Roth), pursuant to which we may sell from time to time up to $10.0 million of shares of our common stock, par value $0.001 per share, through Roth (the ATM Offering). Sales of shares in the ATM Offering, if any, may be made by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act of 1933, as amended, including without limitation directly on the NASDAQ Capital Market, or any other existing trading market for the shares or through a market maker, or, if agreed by the Company and Roth, by any other method permitted by law, including but not limited to in negotiated transactions. The ATM Offering is being made pursuant to the 2014 shelf registration statement. We intend to use the net proceeds from the sale of shares, if any, for operating costs, working capital and general corporate purposes. At the time of the registered direct offering described immediately below, we suspended the ATM Offering. We will continue to evaluate whether to resume the ATM offering in the future. As of March 18, 2014 we had sold 721,677 shares in the ATM Offering for gross proceeds of approximately $2.6 million.
	On March 18, 2014, we sold 2,870,000 shares of our common stock in a registered direct offering pursuant to the 2014 shelf registration statement (the Registered Direct Offering), at a price of $3.15 per share, resulting in net proceeds of approximately $8.4 million.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
USE OF ESTIMATES	'
	(a) USE OF ESTIMATES
	The preparation of financial statements, in conformity with U.S. generally accepted accounting principles, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, and revenues and expenses during the period. Critical accounting policies involved in applying our accounting policies are those that require management to make assumptions about matters that are highly uncertain at the time the accounting estimate was made and those for which different estimates reasonably could have been used for the current period. Critical accounting estimates are also those which are reasonably likely to change from period to period, and would have a material impact on the presentation of our financial condition, changes in financial condition or results of operations. Our most critical accounting estimates relate to accounting policies for strategic alliances and research contract revenues, research and development activities, and stock-based compensation. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances. Actual results could differ from these estimates.
CASH AND CASH EQUIVALENTS	'
	(b) CASH AND CASH EQUIVALENTS
	Cash equivalents consist of highly liquid debt instruments, time deposits, and money market funds with original maturities of three months or less.
INVESTMENTS	'
	(c) INVESTMENTS
	Our investments consist primarily of corporate stock and bonds, government agency bonds, and commercial paper. These investments are classified as available-for-sale securities, which are carried at fair value, with the unrealized holding gains and losses reported as a separate component of accumulated other comprehensive income (loss) until realized. Realized gains and losses from the sale of available-for-sale securities are determined on a specific-identification basis.
	A decline in the market value of any available-for-sale security below cost that is deemed to be other-than-temporary results in a reduction in carrying amount to fair value. The impairment is charged to earnings and a new cost basis for the security is established. To determine whether impairment is other-than-temporary, we consider whether we have the ability and intent to hold the investment until a market price recovery and consider whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary. Evidence considered in this assessment includes the reasons for the impairment, the severity and duration of the impairment, changes in value subsequent to year-end, forecasted performance of the investee, and the general market condition in the geographic area or industry the investee operates. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the effective interest method. Dividend and interest income are recognized when earned.
FAIR VALUE OF FINANCIAL INSTRUMENTS	'
	(d) FAIR VALUE OF FINANCIAL INSTRUMENTS
	The carrying amounts of our financial instruments, as reflected in the accompanying balance sheets, approximate fair value. Financial instruments consist of cash and cash equivalents, investments, accounts receivable, and accounts payable.
PROPERTY AND EQUIPMENT	'
	(e) PROPERTY AND EQUIPMENT
	Property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of assets, which are generally three to five years for equipment and seven years for furniture and fixtures. Leased property meeting certain criteria is capitalized at the lower of the present value of the future minimum lease payments or fair value at the inception of the lease. Amortization of capitalized leased assets is computed on a straight-line basis over the shorter of the lease term or estimated useful life of the asset. We incur maintenance costs with respect to some of our major equipment. Repair and maintenance costs are expensed as incurred.
REVENUE RECOGNITION	'
	(f) REVENUE RECOGNITION
	Revenue is recognized when all four of the following criteria are met (i) a contract is executed, (ii) the contract price is fixed and determinable, (iii) delivery of the services or products has occurred, and (iv) collectability of the contract amounts is considered probable.
	Our collaborative research and development agreements provide for upfront license fees, research payments, and/or substantive milestone payments. Upfront non-refundable fees associated with license and development agreements where we have continuing involvement in the agreement are recorded as deferred revenue and recognized over the estimated service period. If the estimated service period is subsequently modified, the period over which the upfront fee is recognized is modified accordingly on a prospective basis. Non-refundable research and development fees for which no future performance obligations exist are recognized when collection is assured. Substantive milestone payments are considered performance payments and are recognized upon achievement of the milestone if all of the following criteria are met: (i) achievement of the milestone involves a degree of risk and was not reasonably assured at the inception of the arrangement; (ii) substantive effort is involved in achieving the milestone; and (iii) the amount of the milestone payment is reasonable in relation to all of the deliverables and payment terms within the arrangement. Determination of whether a milestone meets the aforementioned conditions involves the judgment of management.
	Research and development revenue from cost-reimbursement and cost-plus fixed-fee agreements is recognized as earned based on the performance requirements of the contract. Revisions in revenues, cost, and billing factors, such as indirect rate estimates, are accounted for in the period of change. Reimbursable costs under such contracts are subject to audit and retroactive adjustment. Contract revenues and accounts receivable reported in the financial statements are recorded at the amount expected to be received. Contract revenues are adjusted to actual upon final audit and retroactive adjustment. Estimated contractual allowances are provided based on management’s evaluation of current contract terms and past experience with disallowed costs and reimbursement levels. Payments received in advance of work performed are recorded as deferred revenue.
	Research and development revenue from fixed-price best efforts arrangements is recognized as earned based on the performance requirements of the contract. Revenue under these arrangements is recognized when delivery to and acceptance by the customer has been received. During the period of performance, recoverable contract costs are accumulated on the balance sheet in other current assets, but no revenue or profit is recorded prior to customer acceptance of the contractually stated deliverables. Recoverable contract costs that are accumulated on the balance sheet include all direct costs associated with the arrangement and an allocation of indirect costs. Payments received in advance of customer acceptance are recorded as deferred revenue. Once customer acceptance has been received, revenue and recoverable contract costs are recognized. Over the course of the arrangement, we routinely evaluate whether revenue and profitability should be recognized in the current period. Any known or probable losses on projects are charged to operations in the period in which such losses are determined.
RESEARCH AND DEVELOPMENT	'
	(g) RESEARCH AND DEVELOPMENT
	Research and development costs are charged to operations as incurred. Advance payments to acquire goods or pay for services that will be consumed or performed in a future period in conducting research and development activities are recorded as an asset when the advance payments are made. Capitalized amounts are recognized as expense when the research and development activities are performed; that is, when the goods without alternative future use are acquired or the service is rendered.
	Research and development costs include internal research and development expenditures (such as salaries and benefits, raw materials, supplies, and allocated facility expenses), contracted services (such as sponsored research, consulting, manufacture of drug supply, and testing services of proprietary research) and development activities and similar expenses associated with collaborative research agreements. These costs are expensed as incurred.
INCOME TAXES	'
	(h) INCOME TAXES
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We recognize the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. We include any interest or penalties incurred in connection with income taxes as part of other expense.
	We have significant net operating loss carryforwards to potentially reduce future federal and state taxable income, and research and experimentation tax credit carryforwards available to potentially offset future federal income taxes. Due to the Company’s prior equity transactions, the Company’s net operating loss and research and experimentation credit carryforwards may expire unutilized due to changes in our ownership as defined within Section 382 of the Internal Revenue Code.
	The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making that assessment. We recorded a full valuation allowance against all estimated net deferred tax assets at December 31, 2013 and 2012.
NET LOSS PER SHARE	'
	(i) NET LOSS PER SHARE
	Basic earnings per share is computed based upon the net loss available to common stock stockholders divided by the weighted average number of common stock shares outstanding during the period. The dilutive effect of common stock equivalents is included in the calculation of diluted earnings per share only when the effect of the inclusion would be dilutive. For the years ended December 31, 2013 and 2012 approximately 1.6 million and 0.7 million common stock equivalent shares associated with our stock option plans and unvested restricted shares and approximately 1.1 million and 1.4 million stock equivalent shares associated with our warrants, respectively, were excluded from the denominator in the diluted loss per share calculation as their inclusion would have been antidilutive.
COMPREHENSIVE INCOME (LOSS)	'
	(j) COMPREHENSIVE INCOME (LOSS)
	Comprehensive income (loss) consists of net loss and unrealized holding gains and losses from available-for-sale securities.
STOCK-BASED COMPENSATION	'
	(k) STOCK-BASED COMPENSATION
	We use the modified prospective method to account for stock-based compensation. Under this method, we measure stock-based compensation expense based on the grant date fair value of the awards which is then recognized over the period during which service is required to be provided. We estimate grant date fair value using the Black-Scholes option-pricing model. Stock-based compensation cost that has been included in expense from continuing operations amounted to $0.9 million and $1.3 million for the years ended December 31, 2013 and 2012, respectively.
LONG-LIVED ASSETS	'
	(l) LONG-LIVED ASSETS
	Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset be tested for possible impairment, we first compare undiscounted cash flows expected to be generated by an asset to the carrying value of the asset. If the carrying value of the long-lived asset is not recoverable on an undiscounted cash flow basis, impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values, and third party independent appraisals, as necessary.
COMMITMENTS AND CONTINGENCIES	'
	(m) COMMITMENTS AND CONTINGENCIES
	Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.
RECENT ACCOUNTING PRONOUNCEMENTS	'
	(n) RECENT ACCOUNTING PRONOUNCEMENTS
	In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (Topic 220). The standard requires that companies present either in a single note or parenthetically on the face of the financial statements, the effect of significant amounts reclassified from each component of accumulated other comprehensive income based on its source and the income statement line items affected by the reclassification. The Company’s adoption of the provisions of this guidance on January 1, 2013 did not have a material impact on our financial position, results of operations, or cash flows.
	There are no other new accounting pronouncements issued but not effective until after December 31, 2013 that are expected to have a significant effect on our financial position or results of operations.
RECLASSIFICATIONS	'
	(o) RECLASSIFICATIONS
	We have made certain reclassifications to prior year accounts to conform to the 2013 presentation.

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Assets and Liabilities Recorded at Fair Value on Recurring Basis on Condensed Balance Sheet	'
	The following table presents information about assets recorded at fair value on a recurring basis on the Balance Sheet at December 31, 2013:
	(In thousands)	Total Carrying Value		Quoted Prices in Active Markets for Identical		Significant Other
		on the Balance Sheet		Assets/Liabilities (Level 1)		Observable Inputs
						(Level 2)
	Assets:
	Cash and cash equivalents	$	5,249	$	5,249	$	—
	Corporate notes and bonds		303		—		303
	U.S. Government and agency securities		503		—		503
	Equity Securities		50		50		—
	Total assets at fair value	$	6,105	$	5,299	$	806
	The following table presents information about assets and liabilities recorded at fair value on a recurring basis on the Balance Sheet at December 31, 2012:
	(In thousands)	Total Carrying		Quoted Prices in Active Markets for		Significant Other
		Value on the		Identical Assets/Liabilities (Level 1)		Observable Inputs
		Balance Sheet				(Level 2)
	Assets:
	Cash and cash equivalents	$	4,150	$	4,150	$	—
	Corporate notes and bonds		6,871		—		6,871
	U.S. Government and agency securities		4,189		—		4,189
	Equity Securities		45		45		—
	Total assets at fair value	$	15,255	$	4,195	$	11,060
Marketable securities	'
	A summary of marketable securities is shown below:
				Gross Unrealized
		Amortized Cost		Gains		Losses		Fair Value
		(in thousands)
	31-Dec-13
	Marketable securities
	Corporate and agency notes and corporate stock	$	878	$	—	$	-22	$	856
	Total marketable securities	$	878	$	—	$	-22	$	856
	31-Dec-12
	Marketable securities
	Corporate and agency notes and corporate stock	$	11,132	$	—	$	-27	$	11,105
	Total marketable securities	$	11,132	$	—	$	-27	$	11,105

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment	'
	Property and equipment consists of the following at December 31:
		2013		2012
		(in thousands)
	Equipment	$	5,777	$	9,750
	Leasehold improvements		6,543		6,563
	Furniture and fixtures		437		437
			12,757		16,750
	Less accumulated depreciation and amortization		-12,243		-15,945
		$	514	$	805

ACCRUED_EXPENSES_AND_OTHER_Tab

ACCRUED EXPENSES AND OTHER (Tables)	12 Months Ended
	Dec. 31, 2013
Other Liabilities Disclosure [Abstract]	'
Schedule Of Accrued Other Expenses	'
	Accrued expenses consist of the following at December 31:
		2013		2012
		(in thousands)
	Payroll, compensation, and benefits	$	905	$	1,490
	Professional fees		534		523
	Other		157		174
	Total accrued expenses	$	1,596	$	2,187

STRATEGIC_ALLIANCES_AND_RESEAR1

STRATEGIC ALLIANCES AND RESEARCH CONTRACTS (Tables)	12 Months Ended
	Dec. 31, 2013
Strategic Alliances And Research Contracts [Abstract]	'
Revenue Earned Under Collaborations and Research Contracts	'
	Revenue earned under these contracts is summarized as follows:
		2013		2012
		(in thousands)
	Hearing Program	$	924	$	4,435
	Foot and Mouth Disease Program		641		2,344
	Vaccine Research Center		157		490
	Malaria Program		1,571		359
	Other strategic alliances and research grants		389		1,725
		$	3,682	$	9,353

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Future Minimum Lease Payments	'
	Future minimum lease payments under our non-cancelable operating leases are as follows (in thousands):
	2014	$	1,168
	2015		246
	2016		124
	2017		128
	2018		131
	2019		113

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Summary of Stock-Based Compensation Expense Related to Employee Stock Options	'
	The following table summarizes stock-based compensation expense related to employee stock options for the years ended December 31, 2013 and 2012, which was allocated as follows:
			Years ended December 31,
			2013			2012
			(in thousands)
	Research and development		$	472		$	864
	General and administrative			408			415
			$	880		$	1,279
Weighted-Average Assumptions Used in Valuation of Stock Option	'
	The weighted-average estimated fair value of employee stock options granted during the 12 months ended December 31, 2013 and 2012 was calculated using the Black-Scholes model with the following weighted-average assumptions:
			2013				2012
	Weighted average risk-free interest rate			1.06	%			1.05	%
	Expected dividend yield			0	%			0	%
	Expected volatility			98.09	%			97.97	%
	Expected life (years)			6.1				6.3
	Weighted-average fair value of options granted		$	1.23			$	1.99
Stock Option Activity	'
	The activity of the plans from December 31, 2011 to December 31, 2013 is as follows:
	(in thousands, except per share data)		Number of Shares Under Option			Weighted Average		Weighted Average			Aggregate
						Exercise Price		Contractual Life			Intrinsic Value
								(years)
	Outstanding at December			1,021			14.77
	31, 2011
	Granted			1,006			2.48
	Cancelled			-618			12.34
	Outstanding at December			1,409			7.06
	31, 2012
	Granted			676			1.57
	Exercised			—			—
	Forfeited			-551			2.29
	Cancelled			-188			13.55
	Stock options outstanding			1,346		$	5.35			7.6	$	306
	at December 31, 2013
	Vested or expected to vest			1,281		$	5.52			7.5	$	271
	at December 31, 2013
	Exercisable at December			919		$	6.88			7	$	77
	31, 2013
Summary of Stock Options Outstanding	'
	The following table summarizes information about our stock options outstanding at December 31, 2013:
			Outstanding								Exercisable
	Range of exercise prices		Number of shares			Weighted average remaining			Weighted average		Number of shares		Weighted average
						contractual life			exercise price				exercise price
		(number of shares in thousands)
	$0.00 – $10.00			1,126			8.3		$	2.53		701	$	2.86
	$10.01 – $20.00			124			3.2			15.82		124		15.82
	$20.01 – $30.00			83			5			23.57		81		23.59
	$30.01 – $41.00			13			0.7			33.21		13		33.21
				1,346			7.6 years		$	5.35		919	$	6.88
Nonvested Restricted Stock Units Activity	'
	The following table summarizes the status of the Company’s unvested restricted stock as of December 31, 2013:
	(in thousands, except per share data)		Number of Shares			Weighted Average Grant			Aggregate Intrinsic
						Date Fair Value			Value
	Non-vested RSU's at December 31, 2011			20		$	7.9
	Granted			—			—
	Vested			-12			—
	Forfeited			-8			—
	Non-vested RSU's at December 31, 2012			—			—
	Granted			730			0.27
	Vested			—			—
	Forfeited			—			—
	Non-vested restricted stock units at			730		$	0.27		$	194
	December 31, 2013
	Expected to vest at December 31, 2013			582		$	0.27		$	155
Summary of Warrants Outstanding	'
	The warrants typically vest six-months after issuance. Outstanding warrants are summarized below (in thousands, except per share amounts):
	Offering Date		Outstanding Warrants			Exercise Price			Expiration Date		Status
	May-09			711,539		$	8.58			5/29/14		Exercisable
	Feb-10			420,000		$	27.5			2/1/15		Exercisable
				1,131,539

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Effective Income Tax Rate Reconciliation, Amount [Abstract]	'
Schedule of Effective Income Tax Rate Reconciliation	'
	A reconciliation of tax credits computed at the statutory federal tax rate (34%) on operating loss before income taxes to the actual income tax expense is as follows (in thousands):
		2013		2012
	Tax provision computed at the statutory rate	$	-3,406	$	-4,779
	State income taxes, net of federal income tax provision		-546		-765
	Book expenses not deductible for tax purposes		11		18
	Nondeductible compensation expense		185		277
	Expired net operating losses and other		1,662		17,305
	Change in valuation allowance for deferred tax assets		2,094		-12,056
	Income tax expense	$	—	$	—
Schedule of Deferred Tax Assets and Liabilities	'
	Significant components of our deferred tax assets are as follows (in thousands):
		2013		2012
	Net operating loss carryforwards	$	98,944	$	95,497
	Research and experimentation tax credit		14,226		14,568
	Property and equipment, principally due to differences in depreciation		-141		-151
	Accrued severance		266		102
	Deferred compensation expense		783		2,053
	Other		197		131
	Total deferred tax assets		114,275		112,200
	Valuation allowance		-114,275		-112,200
	Net deferred tax assets	$	—	$	—

QUARTERLY_RESULTS_Tables

QUARTERLY RESULTS (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information	'
	Our unaudited quarterly information is as follows:
	2013 (unaudited)	Q1		Q2		Q3		Q4
		(in thousands, except per share data)
	Revenue	$	1,207	$	748	$	1,582	$	145
	Operating Loss	$	-3,054	$	-3,131	$	-2,963	$	-1,146
	Net Loss	$	-3,045	$	-3,126	$	-2,961	$	-887
	Basic and Diluted Loss Per Share	$	-0.24	$	-0.24	$	-0.23	$	-0.07
	2012 (unaudited)	Q1		Q2		Q3		Q4
		(in thousands, except per share data)
	Revenue	$	3,164	$	2,540	$	2,128	$	1,521
	Operating Loss	$	-3,203	$	-3,673	$	-4,051	$	-3,170
	Net Loss	$	-3,194	$	-3,663	$	-4,039	$	-3,159
	Basic and Diluted Loss Per Share	$	-0.25	$	-0.28	$	-0.31	$	-0.24

Recovered_Sheet1

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Significant Accounting Policies [Line Items]	'	'
Stock Granted During Period, Value, Share-based Compensation, Gross	$0.90	$1.30
Stock Option	'	'
Significant Accounting Policies [Line Items]	'	'
Common stock equivalent shares excluded from the denominator in the diluted loss per share calculation	1.6	0.7
Warrant	'	'
Significant Accounting Policies [Line Items]	'	'
Common stock equivalent shares excluded from the denominator in the diluted loss per share calculation	1.1	1.4

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
Fair Value, Measurement Inputs, Disclosure [Line Items]	'
Marketable securities maturities	'less than twelve months

Assets_and_Liabilities_Recorde

Assets and Liabilities Recorded at Fair Value on Recurring Basis on Condensed Balance Sheet (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Assets:	'	'	'
Cash and cash equivalents	$5,249	$4,150	$4,114
Fair Value, Measurements, Recurring	'	'	'
Assets:	'	'	'
Cash and cash equivalents	5,249	4,150	'
Corporate notes and bonds	303	6,871	'
U.S. Government and agency securities	503	4,189	'
Total assets at fair value	6,105	15,255	'
Fair Value, Measurements, Recurring | Equity Security	'	'	'
Assets:	'	'	'
Total assets at fair value	50	45	'
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)	'	'	'
Assets:	'	'	'
Cash and cash equivalents	5,249	4,150	'
Corporate notes and bonds	0	0	'
U.S. Government and agency securities	0	0	'
Total assets at fair value	5,299	4,195	'
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) | Equity Security	'	'	'
Assets:	'	'	'
Total assets at fair value	50	45	'
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)	'	'	'
Assets:	'	'	'
Cash and cash equivalents	0	0	'
Corporate notes and bonds	303	6,871	'
U.S. Government and agency securities	503	4,189	'
Total assets at fair value	806	11,060	'
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Equity Security	'	'	'
Assets:	'	'	'
Total assets at fair value	$0	$0	'

Summary_of_Marketable_Securiti

Summary of Marketable Securities (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	$878	$11,132
Gross Unrealized Gains	0	0
Gross Unrealized Losses	-22	-27
Fair Value	856	11,105
Corporate and Agency Notes and Corporate Stock [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	878	11,132
Gross Unrealized Gains	0	0
Gross Unrealized Losses	-22	-27
Fair Value	$856	$11,105

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended	12 Months Ended
	Nov. 30, 2013	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'	'	'
Depreciation and amortization	'	'	$174,000	$242,000
Gain (loss) on disposition of property plant equipment, total	300,000	'	286,000	0
Impairment of Long-Lived Assets to be Disposed of	'	200,000	229,000	0
Other Income	'	'	$300,000	'

Property_and_Equipment_Detail

Property and Equipment (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$12,757	$16,750
Less accumulated depreciation and amortization	-12,243	-15,945
Property, Plant and Equipment, Net, Total	514	805
Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	5,777	9,750
Land Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	6,543	6,563
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$437	$437

Accrued_Expenses_Detail

Accrued Expenses (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Other Expenses [Line Items]	'	'
Payroll, compensation, and benefits	$905	$1,490
Professional fees	534	523
Other	157	174
Total accrued expenses	$1,596	$2,187

Recovered_Sheet2

Strategic Alliances and Research Contracts - Additional Information (Detail) (USD $)

1 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Feb. 28, 2014

Feb. 28, 2014

Feb. 28, 2014

Feb. 28, 2014

Jan. 31, 2007

Dec. 31, 2013

Dec. 31, 2012

Jan. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Aug. 31, 2010

Feb. 28, 2014

Jun. 30, 2010

Feb. 28, 2010

Dec. 31, 2013

Dec. 31, 2012

Nov. 30, 2009

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2012

Jul. 31, 2009

Dec. 31, 2013

Dec. 31, 2012

Aug. 31, 2009

Dec. 31, 2013

Dec. 31, 2012

31-May-12

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Oct. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Subsequent Event

Clinical Milestones

Regulatory Milestones

Sales-Based Milestones

U.s. Department Of Homeland Security

U.s. Department Of Homeland Security

U.s. Department Of Homeland Security

Novartis

Novartis

Novartis

Novartis

Novartis

Novartis

Novartis

DHS Exercises

DHS Exercises

DHS Exercises

DHS Exercises

Vaccine Research Center

Vaccine Research Center

Vaccine Research Center

Vaccine Research Center

Vaccine Research Center

Vaccine Research Center

Vaccine Research Center

Vaccine Research Center

Other Strategic Alliances and Research Grants

Other Strategic Alliances and Research Grants

Other Strategic Alliances and Research Grants

Other Strategic Alliances and Research Grants

Other Strategic Alliances and Research Grants

Other Strategic Alliances and Research Grants

Other Strategic Alliances and Research Grants

Other Strategic Alliances and Research Grants

Other Strategic Alliances and Research Grants

NMRC Malaria Vaccine Development

NMRC Malaria Vaccine Development

NMRC Malaria Vaccine Development

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

U.s. Department Of Homeland Security

U.s. Department Of Homeland Security

U.s. Department Of Homeland Security

U.s. Department Of Homeland Security

SAIC Frederick

SAIC Frederick

NIAID

NIAID

NIAID

NIAID

Business Innovation And Research Grant

Business Innovation And Research Grant

Business Innovation And Research Grant

Immune Response In Newborns

Immune Response In Newborns

Immune Response In Newborns

Cell Line and Vector Production Technology

Cell Line and Vector Production Technology

NIAID

New Antigens For Malaria Vaccine Development

New Antigens For Malaria Vaccine Development

New Antigens For Malaria Vaccine Development

New Antigens For Malaria Vaccine Development

Business Innovation And Research Grant

Business Innovation And Research Grant

Business Innovation And Research Grant

Business Innovation And Research Grant

Business Innovation And Research Grant

Business Innovation And Research Grant

Strategic Alliances Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-refundable upfront license fee

'

'

'

'

'

'

'

$5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Value of common stock issued

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of common stock issued

'

'

'

'

'

'

'

3,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue to be recognized from the non-refundable upfront license fee

'

'

'

'

'

'

'

3,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Upfront payment

'

'

'

'

'

'

'

'

0

78,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Upfront payment received for research

'

'

'

'

'

'

'

'

400,000

800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestones payments receivable

'

'

'

'

'

'

'

'

206,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestones payments receivable for achievement of preclinical development activities

'

'

'

'

'

'

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestones payments receivable for achievement of clinical milestones

'

'

'

'

'

'

'

'

26,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestones payments receivable for receipt of regulatory approvals

'

'

'

'

'

'

'

'

45,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestones payments receivable for achievement sales milestones

'

'

'

'

'

'

'

'

135,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestone payment received in successful completion of preclinical development activities

'

'

'

'

'

'

'

'

0

0

300,000

300,000

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount receivable under manufacture clinical trial material

'

'

'

'

'

'

'

'

'

'

'

'

14,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount recognized from services performed under this new agreement

'

'

'

'

'

3,000

600,000

'

400,000

3,400,000

'

'

'

'

'

'

600,000

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Program funding received under agreement

'

'

'

'

6,000,000

'

'

'

'

'

'

'

'

'

'

3,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,500,000

'

'

Maximum amount receivable on annual renewal options under contract were exercised

'

'

'

'

15,100,000

'

'

'

'

'

'

'

'

'

'

700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum amount receivable on annual renewal options under modified agreement

'

'

'

'

20,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue recognized under the contract

'

'

'

'

'

20,700,000

'

'

'

'

'

'

'

'

'

'

5,100,000

'

'

5,800,000

157,000

400,000

'

'

8,000

121,000

'

'

'

'

'

'

'

'

'

'

'

'

Proceed from renewal of agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total value of contract

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

22,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Grant received from NIAID

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

600,000

'

'

2,500,000

'

'

590,000

'

'

'

'

'

'

'

'

Revenue recognized under research grants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

133,000

94,000

'

200,000

800,000

'

122,000

109,000

300,000

1,300,000

2,300,000

'

1,400,000

0

Milestone method, revenue recognized

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue to be recognized under milestone method

'

$24,000,000

$45,000,000

$135,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue_Earned_Contract_Detail

Revenue Earned Contract (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Revenue Earned Contract [Line Items]	'	'	'	'	'	'	'	'	'	'
Revenues	$145	$1,582	$748	$1,207	$1,521	$2,128	$2,540	$3,164	$3,682	$9,353
Hearing Program	'	'	'	'	'	'	'	'	'	'
Revenue Earned Contract [Line Items]	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	924	4,435
Foot and Mouth Disease Program	'	'	'	'	'	'	'	'	'	'
Revenue Earned Contract [Line Items]	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	641	2,344
Vaccine Research Center	'	'	'	'	'	'	'	'	'	'
Revenue Earned Contract [Line Items]	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	157	490
Malaria Program	'	'	'	'	'	'	'	'	'	'
Revenue Earned Contract [Line Items]	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	1,571	359
Other strategic alliances and research grants	'	'	'	'	'	'	'	'	'	'
Revenue Earned Contract [Line Items]	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	$389	$1,725

Recovered_Sheet3

Commitments And Contingencies - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended				12 Months Ended
	Sep. 25, 2012	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Sep. 30, 2012	Dec. 31, 2013	Dec. 31, 2012
Commitment [Line Items]	'	'	'	'	'	'	'
Operating Leases, Rent Expense	'	'	'	'	'	$800,000	$800,000
Non Refundable Initial License Fee	'	'	'	'	'	50,000	'
Percentage Of Operating Cost And Conserve Capital	30.00%	'	'	'	'	'	'
Severance Costs	'	'	'	'	700,000	'	'
Severance Cost Payable	'	'	'	'	'	817,000	469,000
Restructuring and Related Cost, Number of Positions Eliminated	23	'	'	'	'	'	'
Restructuring Costs, Total	'	1,000,000	300,000	'	'	200,000	'
Payments of Debt Restructuring Costs	'	'	$90,000	$85,000	'	'	'

Future_Minimum_Payments_of_Non

Future Minimum Payments of Non-cancelable Operating Leases (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Operating Leases Minimum Lease Payments [Line Items]	'
2014	$1,168
2015	246
2016	124
2017	128
2018	131
2019	$113

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

In Millions, except Share data, unless otherwise specified

Jan. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Jun. 11, 2013

Dec. 31, 2011

Dec. 31, 2013

31-May-12

Dec. 31, 2013

Mar. 18, 2014

Jan. 31, 2014

Mar. 31, 2014

Mar. 18, 2014

Mar. 31, 2014

Mar. 18, 2014

Feb. 11, 2014

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Nov. 30, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

CEO Inducement Plan [Member]

CEO Inducement Plan [Member]

Stock Option [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Roth Equity Distribution Agreement [Member]

Roth Equity Distribution Agreement [Member]

ATM Offering [Member]

Employee Stock Option [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Common Stock [Member]

Preferred Stock [Member]

Preferred Stock [Member]

Warrant [Member]

Treasury Stock [Member]

Board Of Directors Chairman [Member]

Series B Preferred Stock [Member]

Stock Incentive Plan 2011 [Member]

Stock Incentive Plan 2011 [Member]

Stock Incentive Plan 2011 [Member]

Stock Incentive Plan 2011 [Member]

Stock Incentive Plan 2002 [Member]

Stock Incentive Plan 2002 [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

Weighted Average [Member]

Registered Direct Offering [Member]

Registered Direct Offering [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Roth Equity Distribution Agreement [Member]

Subsequent Event [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Subsequent Event [Member]

Class Of Warrant Or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

220,383

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant Exercise Price

'

'

'

20.16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued during period, shares, new issues

75,000,000

'

'

'

'

'

'

'

721,677

'

'

'

'

'

'

'

730,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares reserved for future issuance

'

'

'

'

'

'

'

'

'

'

'

2,870,000

'

721,677

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redeem rights per right

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of common stock acquired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares authorized

'

5,000,000

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,400,000

600,000

'

'

'

30,000

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock option

'

1,346,000

1,409,000

'

1,021,000

83,333

'

1,345,542

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

640,000

'

371,876

11,750

'

'

'

'

'

Exercisable Number of shares

'

919,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock holder equity right shares price per shares

'

$32

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of public offering included in registration statement filed with sec

'

'

'

'

'

'

'

'

'

$75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued during period, value, new issues

'

'

'

'

'

'

'

'

'

'

8.4

'

2.6

'

'

'

'

'

11.6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par or Stated Value Per Share

'

$0.00

$0.00

'

'

'

'

'

'

'

'

$3.15

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of Stock, Number of Shares Issued in Transaction

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

200,000

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

'

'

'

'

'

'

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,035,125

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price

'

'

'

'

'

'

$2.54

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$41

'

$1.56

'

$6.88

Fair Value Assumptions, Risk Free Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.85%

1.66%

1.00%

0.81%

'

Weighted Average Period Recognisition Of Stock Based Compensation

'

'2 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year 8 months 12 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding restricted stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

730,000

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.20

'

'

'

'

$0.50

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercisable weighted average term

'

'6 years 1 month 6 days

'6 years 3 months 18 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Summary_of_Stock_Based_Compens

Summary of Stock Based Compensation Expense Related to Employee Stock Options (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Non-cash charges for stock-based compensation	$880	$1,279
Research and development	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Non-cash charges for stock-based compensation	472	864
General and administrative	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Non-cash charges for stock-based compensation	$408	$415

Black_Scholes_Model_Weighted_A

Black Scholes Model Weighted Average Assumptions Used to Calculate Weighted Average Estimated Fair Value of Employee Stock Options Granted (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used [Line Items]	'	'
Weighted average risk-free interest rate	1.06%	1.05%
Expected dividend yield	0.00%	0.00%
Expected volatility	98.09%	97.97%
Expected life (years)	'6 years 1 month 6 days	'6 years 3 months 18 days
Weighted-average fair value of options granted	$1.23	$1.99

Stock_Option_Activity_Detail

Stock Option Activity (Detail) (USD $)	12 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Number of shares	'	'
Stock options outstanding	1,409	1,021
Granted	676	1,006
Exercised	0	'
Forfeited	-551	'
Cancelled	-188	-618
Stock options outstanding	1,346	1,409
Vested or expected to vest	1,281	'
Exercisable	919	'
Weighted average exercise price	'	'
Stock options outstanding	$7.06	$14.77
Granted	$1.57	$2.48
Exercised	$0	'
Forfeited	$2.29	'
Cancelled	$13.55	$12.34
Stock options outstanding	$5.35	$7.06
Vested or expected to vest	$5.52	'
Exercisable	$6.88	'
Weighted average contractual life (years)	'	'
Stock options outstanding	'7 years 7 months 6 days	'
Vested or expected to vest	'7 years 6 months	'
Exercisable	'7 years	'
Aggregate intrinsic value	'	'
Stock options outstanding	$306	'
Vested or expected to vest	271	'
Exercisable	$77	'

Summary_of_Stock_Options_Outst

Summary of Stock Options Outstanding (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Outstanding Number of shares	1,346
Outstanding Weighted average remaining contractual life (in years)	'7 years 7 months 6 days
Outstanding Weighted average exercise price	$5.35
Exercisable Number of shares	919
Exercisable Weighted average exercise price	$6.88
Range 1	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise prices, minimum	$0
Range of exercise prices, maximum	$10
Outstanding Number of shares	1,126
Outstanding Weighted average remaining contractual life (in years)	'8 years 3 months 18 days
Outstanding Weighted average exercise price	$2.53
Exercisable Number of shares	701
Exercisable Weighted average exercise price	$2.86
Range 2	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise prices, minimum	$10.01
Range of exercise prices, maximum	$20
Outstanding Number of shares	124
Outstanding Weighted average remaining contractual life (in years)	'3 years 2 months 12 days
Outstanding Weighted average exercise price	$15.82
Exercisable Number of shares	124
Exercisable Weighted average exercise price	$15.82
Range 3	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise prices, minimum	$20.01
Range of exercise prices, maximum	$30
Outstanding Number of shares	83
Outstanding Weighted average remaining contractual life (in years)	'5 years
Outstanding Weighted average exercise price	$23.57
Exercisable Number of shares	81
Exercisable Weighted average exercise price	$23.59
Range 4	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise prices, minimum	$30.01
Range of exercise prices, maximum	$41
Outstanding Number of shares	13
Outstanding Weighted average remaining contractual life (in years)	'8 months 12 days
Outstanding Weighted average exercise price	$33.21
Exercisable Number of shares	13
Exercisable Weighted average exercise price	$33.21

Summary_of_NonVested_Restricte

Summary of Non-Vested Restricted Stock (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Weighted Average Grant Date Fair Value	'	'
Granted	$1.23	$1.99
Restricted Stock	'	'
Number of shares	'	'
Number of Units, Beginning Balance	0	20
Granted	730	0
Vested	0	-12
Forfeited	0	-8
Number of Units, Ending Balance	730	0
Number of Units, Expected to vest at December 31, 2013	582	'
Weighted Average Grant Date Fair Value	'	'
Beginning Balance	$0	$7.90
Granted	$0.27	$0
Vested	$0	$0
Forfeited	$0	$0
Ending Balance	$0.27	$0
Weighted Average Grand Date Fair Value, Expected to vest at December 31, 2013	$0.27	'
Aggregate Intrinsic Value	'	'
Aggregate Intrinsic Value	$194	'
Aggregate Value, Expected to vest at December 31, 2013	$155	'

Outstanding_Warrants_to_Purcha

Outstanding Warrants to Purchase Shares of Common Stock (Detail)	Dec. 31, 2013	Jun. 11, 2013	Dec. 31, 2013	Dec. 31, 2013
In Thousands, unless otherwise specified			Warrant 1	Warrant 2
Class of Warrant or Right [Line Items]	'	'	'	'
Offering Date	'	'	'2009-05	'2010-02
Outstanding Warrants	1,131,539	'	711,539	420,000
Exercise Price	'	20.16	8.58	27.5
Expiration Date	'	'	'5/29/2014	'2/1/2015
Status	'	'	'Exercisable	'Exercisable

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Line items [Line Items]	'	'
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%	'
Operating Loss Carryforwards	$250,800,000	'
Research and experimentation tax credit	14,226,000	14,568,000
Deferred Tax Assets Tax Credit Carryforward Research And Experimentation Tax Credit Expired	$300,000	'

Income_Tax_Reconciliation_at_S

Income Tax Reconciliation at Statutory Federal Income Tax Rate (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Income Tax Expense Benefit At Federal Statutory Income Tax Rate [Line Items]	'	'
Tax provision computed at the statutory rate	($3,406)	($4,779)
State income taxes, net of federal income tax provision	-546	-765
Book expenses not deductible for tax purposes	11	18
Nondeductible compensation expense	185	277
Expired net operating losses and other	1,662	17,305
Change in valuation allowance for deferred tax assets	2,094	-12,056
Income tax expense	$0	$0

Deferred_Tax_Assets_Detail

Deferred Tax Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred Tax Assets [Line Items]	'	'
Net operating loss carryforwards	$98,944	$95,497
Research and experimentation tax credit	14,226	14,568
Property and equipment, principally due to differences in depreciation	-141	-151
Accrued severance	266	102
Deferred compensation expense	783	2,053
Other	197	131
Total deferred tax assets	114,275	112,200
Valuation allowance	-114,275	-112,200
Net deferred tax assets	$0	$0

Unaudited_Quarterly_Detail

Unaudited Quarterly (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Line Items]	'	'	'	'	'	'	'	'	'	'
Revenue	$145	$1,582	$748	$1,207	$1,521	$2,128	$2,540	$3,164	$3,682	$9,353
Operating Loss	-1,146	-2,963	-3,131	-3,054	-3,170	-4,051	-3,673	-3,203	-10,294	-14,097
Net loss	($887)	($2,961)	($3,126)	($3,045)	($3,159)	($4,039)	($3,663)	($3,194)	($10,019)	($14,055)
Basic and diluted net loss per share	($0.07)	($0.23)	($0.24)	($0.24)	($0.24)	($0.31)	($0.28)	($0.25)	($0.77)	($1.09)

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)

1 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

In Millions, except Share data, unless otherwise specified

Jan. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Mar. 18, 2014

Feb. 28, 2014

Jan. 23, 2014

Mar. 31, 2014

Mar. 18, 2014

Mar. 31, 2014

Mar. 18, 2014

Feb. 11, 2014

Feb. 28, 2014

Feb. 28, 2014

Feb. 28, 2014

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Roth Equity Distribution Agreement

Roth Equity Distribution Agreement

Roth Equity Distribution Agreement

Clinical Milestones

Regulatory Milestones

Sales-Based Milestones

Registered Direct Offering

Registered Direct Offering

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase in additional capital to be raised, shelf registartion

'

'

'

'

'

$75

'

'

'

'

'

'

'

'

Milestone method, revenue recognized

'

'

'

'

2

'

'

'

'

'

'

'

'

'

Revenue to be recognized under milestone method

'

'

'

'

'

'

'

'

'

'

'

24

45

135

Sale of stock, price per share

'

'

'

'

'

'

'

'

'

'

$10

'

'

'

Common stock, no par value

'

'

'

'

'

'

'

'

'

'

$0.00

'

'

'

Stock issued during period, shares, new issues

75,000,000

'

'

721,677

'

'

'

'

'

'

'

'

'

'

Stock issued during period, value, new issues

'

'

'

'

'

'

$8.40

'

$2.60

'

'

'

'

'

Shares reserved for future issuance

'

'

'

'

'

'

'

2,870,000

'

721,677

'

'

'

'

Common stock, par or stated value per share

'

$0.00

$0.00

'

'

'

'

$3.15

'

'

'

'

'

'